Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia.

Thibaut F, Cordier B, Kuhn JM

Acta psychiatrica Scandinavica1 Jun 1993Cited by 37 (Europe PMC)

PMID8356897DOI10.1111/j.1600-0447.1993.tb03402.xPepBankPUB-08356897

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanCase report or seriesEfficacy outcome
In men with severe paraphilia, triptorelin ended deviant sexual behavior in 5 cases.
In plain wordsIn men with severe paraphilia, triptorelin ended deviant sexual behavior in 5 cases.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseDeviant sexual behavior
Study
n = 6
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Measurements
Men whose deviant sexual behavior ended
5 patients
triptorelin-treated men (of 6)
Source sentences
Summary
In 5 cases, the treatment ended their deviant sexual behavior and markedly decreased their sexual fantasies and activities without further significant side effects than those related to hypoandrogenism.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689701
02HumanCase report or seriesEfficacy outcome
In men with severe paraphilia, triptorelin markedly decreased sexual fantasies in 5 cases.
In plain wordsIn men with severe paraphilia, triptorelin markedly decreased sexual fantasies in 5 cases.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSexual fantasies
Study
n = 6
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Measurements
Men with markedly decreased sexual fantasies
5 patients
triptorelin-treated men (of 6)
Source sentences
Summary
In 5 cases, the treatment ended their deviant sexual behavior and markedly decreased their sexual fantasies and activities without further significant side effects than those related to hypoandrogenism.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689702
03HumanCase report or seriesEfficacy outcome
In men with severe paraphilia, triptorelin markedly decreased sexual activities in 5 cases.
In plain wordsIn men with severe paraphilia, triptorelin markedly decreased sexual activities in 5 cases.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSexual activities
Study
n = 6
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Measurements
Men with markedly decreased sexual activities
5 patients
triptorelin-treated men (of 6)
Source sentences
Summary
In 5 cases, the treatment ended their deviant sexual behavior and markedly decreased their sexual fantasies and activities without further significant side effects than those related to hypoandrogenism.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689703
04HumanCase report or seriesSafety outcome
In men with severe paraphilia who improved, triptorelin caused no further significant side effects beyond those related to hypoandrogenism.
In plain wordsIn men with severe paraphilia who improved, no further significant side effects occurred beyond those related to low androgen levels.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSignificant side effects
Study
n = 5
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Source sentences
Summary
In 5 cases, the treatment ended their deviant sexual behavior and markedly decreased their sexual fantasies and activities without further significant side effects than those related to hypoandrogenism.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689704
05HumanCase report or seriesOther
In a man with severe paraphilia, relapse occurred within 10 weeks after triptorelin treatment stopped at the end of the first year.
In plain wordsIn a man with severe paraphilia, relapse occurred within 10 weeks after triptorelin stopped at the end of the first year.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableRelapse after withdrawal
Study
n = 1
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Source sentences
Summary
One patient interrupted the treatment at the end of the first year and relapsed within 10 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689707
06HumanCase report or seriesEfficacy outcome
In men with severe paraphilia, clinical improvement accompanied a gradual testosterone decline to castration values within the first month.
In plain wordsIn men with severe paraphilia, improvement accompanied a testosterone decline to castration values during the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePlasma testosterone
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Source sentences
Summary
This clinical improvement was parallel to the gradual decrease of plasma testosterone level to castration values within the first month.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689705
07HumanCase report or seriesEfficacy outcome
In men with severe paraphilia, triptorelin benefit persisted during follow-up ranging from 7 months to 3 years.
In plain wordsIn men with severe paraphilia, triptorelin benefit persisted during follow-up ranging from 7 months to 3 years.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMaintenance of clinical benefit
Study
n: not reported in source
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
3.75 mg per month · intramuscularAs given in this study (human).
Source sentences
Summary
The beneficial effect of this treatment had been maintained at follow-up varying from 7 months to 3 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Six men with severe paraphilia had been treated with depot gonadotrophin luteinizing releasing hormone analogue (GnRHa) (triptorelin 3.75 mg per month intramuscularly).
Report a problemFND-0835689706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.